Additional ASO therapies are under investigation for other genetically defined forms of ALS, such as those involving FUS and C9orf72 mutations, and are also being explored in Huntington’s disease, Alzheimer’s disease, and frontotemporal dementia. Here, C9orf72 is linked to early-onset autosomal dominant Alzheimer disease.